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A B S T R A C T
Activity-guided fractionation of an ethanol-soluble extract of the leaves of Swietenia 
macrophylla King, Meliaceae, led to several fractions. As a result, sample Sm13-16, 23 had 
the most promising activity against phospholipases A2 (PLA2), Asp49 and Lys49 types. This 
fraction inhibited PLA2 activity of the Asp49 PLA2, when aggregated substrate was used. On 
the other hand, this activity was weakly neutralized when monodispersed substrate was 
used. In addition, Sm13-16, 23 inhibited, in a dose dependent manner, the cytotoxicity, 
myotoxicity and edema induced by PLA2s, as well as the anticoagulant activity of Asp49 
PLA2. Overall, this fraction exhibited a better inhibition of the toxic activities induced by the 
Lys49 PLA2 than those caused by the Asp49 PLA2. The spectral data of Sm13-16, 23 suggested 
the presence of aromatic compounds (UV O max (nm) 655, 266, and 219; IR O max KBr (cm-1): 
~ 3600-3000 (OH), 2923.07 and 1438.90 (C-H), 1656.69 (C = O), 1618.63 and 1607.67 (C-O), 1285.47-
772.60). We suggest that phenolic compounds could interact and inhibit the toxins by several 
mechanisms. Further analysis of the compounds present in the active fraction could be a 
relevant contribution in the treatment of accidents caused by snake envenomation.
© 2013 Brazilian Society of Pharmacognosy. Published by 
Elsevier Editora Ltda. 
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Introduction
Snakebites represent a relevant public health issue in 
many regions of the world, particularly in tropical and 
subtropical countries of Africa, Asia, Latin America and 
Oceania (Williams et al., 2010). The pathophysiological effects 
observed in ophidian bites are a combination of the action of 
several enzymes, non-enzymatic proteins and peptides, which 
include phospholipases A2, hemorrhagic metalloproteases, 
serine proteases neurotoxins, cytotoxins, and cardiotoxins, 
among others (Markland, 1997). The most important and 
abundant muscle-damaging components in snake venoms are 
phospholipases A2 (PLA2; EC 3.1.1.4). These enzymes hydrolyze 
the sn-2 ester bond of glycerophospholipids, releasing a fatty 
acid and a lysophospholipid (Kini, 2003). In addition, PLA2 can 
induce several pharmacological also effects such as edema, 
modulation of platelet aggregation, as well as neurotoxicity, 
myotoxicity and anticoagulation (Kini, 2003; Six and Dennis, 
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2000). Venom PLA2 are classified into groups I or II, based on 
their sequence and the pairing of the disulphide groups. Group 
I PLA2 are found in the venoms of Elapidae snakes, whereas 
group II PLA2 are present in the venoms of Viperidae snakes 
(Six and Dennis, 2000). The group II is further divided into 
two main subgroups: Asp49 and Lys49 (PLA2 homologues) 
variants. In the latter, the aspartic acid residue at position 
49, critically involved in calcium binding and essential for 
catalytic activity, is replaced by lysine. Due to this and other 
critical substitutions, the Lys49 PLA2 can not bind calcium 
efficiently and are considered to be enzymatically inactive 
(Arni and Ward, 1996; Lomonte et al., 2003). Although catalytic 
activity has been shown to play a role in the toxic actions of 
some venom PLA2, it is not essential in the case of Lys49 PLA2, 
which uses non-enzymatic mechanisms to alter membrane 
homeostasis (Lomonte et al., 2003).
The therapy for snakebite envenomations has been based 
on the intravenous administration of antivenoms (Bon, 
1996). However, it has been demonstrated that antivenoms 
have a limited efficacy against the local tissue damaging 
activities of venoms (Gutiérrez et al., 1998). Thus, there is 
the need to search for additional approaches that may be 
useful complement to conventional antivenom therapy. 
In this way, the search for specific PLA2 inhibitors could 
complement the traditional therapy of envenomings and, in 
addition, may contribute to finding new anti-inflammatory 
agents. 
Medicinal plants represent a vital source of novel 
bioactive compounds with several pharmacological 
activities that have contributed directly in the search 
of alternatives against ophidian envenomation or as a 
complement to conventional antivenom therapy (Soares et 
al., 2005). The species Swietenia macrophylla King, Meliaceae, 
was selected as a promising lead after the bioassay-
screening of several ethanolic plant extracts, because of 
its significant neutralizing activity against Bothrops asper 
venom and PLA2 isolated from the this venom (Pereañez 
et al., 2010). Swietenia species are found in neotropics 
regions (Brown et al., 2003; Gullison et al., 1996). The tree 
can grow up to a height of 40-60 m and is native to tropical 
America, Mexico, South America, and India (Brown et 
al., 2003). Organic and aqueous extracts of S. macrophylla 
seeds possess a wide array of biological properties such 
as anti-diabetic (Maiti et al., 2007a), anti-diarrhoeal (Maiti 
et al., 2007b), anti-inflammatory, anti-mutagenic, anti-
tumor-promoting (Amelia et al., 1996), antimicrobial, 
and antimalaric (Maiti et al., 2007c; Soediro et al., 1990). 
Additionally, its leaves yield essential oils which contain 
himachalene, germacrene D, germacrene A, cadina-1, 
4-diene, hexadecanoic acid, and ethyl hexadecanoate 
(Soares et al., 2003). Due to the promising activity of S. 
macrophylla in the preliminary screening against Bothrops 
asper venom and PLA2 (Pereañez et al., 2010), the aim of 
this study was to follow up, phytochemical and biological 
analysis through, the ability of fractions derived from this 
plant to inhibit myotoxic PLA2. 
Materials and methods
Venoms, toxins and animals
Venoms of Crotalus durissus cumanensis  (Colombian 
rattlesnake), Bothrops asper and Bothrops atrox were obtained 
from Antioquia University Serpentarium, Colombia. Cdcum6, 
PLA2 (CB) from the crotoxin complex (Asp49) and B. atrox 
myotoxin I (Lys49) were purified those previously described 
(Núñez et al., 2004; Pereañez et al., 2009). Doses used in each 
experiment were chosen in order to obtain comparable effects. 
Swiss Webster mice of 20-22 g body weight were utilized for 
determination of toxic activities, in accordance with guidelines 
of the Universidad de Antioquia Ethics Committee (Medellín, 
Colombia).
Plant material
One kg of Swietenia macrophylla King, Meliaceae, leaves were 
collected in tropical and premountain forests of Medellín, 
Colombia, 1600 m.s.l (6º15’41” N, 75º34’35.5” W). Voucher 
specimen (TL-103) identified by Leon Morales, was deposited 
in the Herbarium of the Universidad Nacional Gabriel Gutiérrez 
Villegas (MEDEL).
Extraction and bioassay-guided fractionation of Swietenia 
macrophylla
The dried and milled plant materials was extracted three 
times overnight with 90% ethanol. The resultant ethanol 
extract was concentrated at a temperature below 40°C to a 
semisolid paste using a rotary evaporator (Büchi-124 Flawil, 
Switzerland). The ethanol-soluble extract of leaves of S. 
macrophylla was submitted to an initial fractionation using 
an open silica gel column eluted with a gradient of n-hexane: 
dichloromethane: methanol, which resulted in 22 fractions. 
The fractionation was followed by the inhibition of the PLA2 
activity bioassay, from which the most active fractions were 
combined into one single sample labeled as Sm13-16. A 
successive fractionation of Sm13-16 was carried out by silica 
gel and a gradient of organic solvents, which from 30 sub-
fractions were obtained. The inhibition of PLA2 enzymatic 
activity induced by B. asper whole venom (at a 1:10 w/w 
(venom: fraction) ratio in egg yolk assay) was performed to 
each of the thirty subfractions and further inhibition assays 
of Cdcum6 (Asp49, enzymatic activity) and B. atrox myotoxin 
I (Lys49, cytotoxic activity) were performed only on the most 
active fractions. Sample Sm13-16, 23 was the most promising 
lead, so further characterization was carried out with this 
fraction. For all the inhibition assays, fractions were dissolved 
in 3% DMSO in PBS.
Characterization of the sample
The preliminary colorimetric phytochemical analysis was 
carried out on the sample Sm13-16, 23, according to the 
methods described by Trease (2002). Additionally, an infrared 
(IR) spectrum of Sm 13-16, 23 was taken in KBr, using a Fourier 
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Transform Infrared (FT-IR) (4000 - 400 cm) (Perkin-Elmer). The 
UV-Vis spectrum (200 - 800 nm) of the fraction was taken 
in methanol, using a UV-Vis Spectrophometer (UV-1700 
PharmarSpec, Shimadzu). 
Inhibition of PLA2 activity
Egg yolk as substrate
PLA2 activity was assayed according to the method reported by 
Dole (1956), with titration of free fatty acids released from egg 
yolk phospholipids suspended in 1% Triton X-100, 0.1 M Tris-
HCl, 0.01 M CaCl2, pH 8.5 buffer, using 20 μg of Cdcum6 (Asp49). 
The time of reaction was 15 min at 37°C. The amount of protein 
was selected from the linear region of dose-activity curves. For 
inhibition experiments, 1:0.25, 1:0.5, 1:1, 1:2, 1:5 and 1:10 w/w 
(toxin: fraction) ratios were mixed, and incubated for 30 min 
at 37°C before PLA2 activity determination. The results were 
indicated as inhibition percentage, where 0 % is the activity 
induced by PLA2 alone. 
4-Nitro-3-octanoyloxy-benzoic acid (4N3OBA) as substrate
Measurements of enzymatic activity using the monodisperse 
substrate 4N3OBA were performed according to the method 
described by Holzer and Mackessy (1996) and adapted for a 
96-well ELISA plate (Ponce-Soto et al., 2002). The standard 
assay contained 200 μl of buffer (10 mM Tris-HCl, 10 mM 
CaCl2, 100 mM NaCl, pH 8.0), 20 μl of 10 mM of substrate 
(4NO3BA), 20 μl of sample (PLA2) and 20 μl of water. The 
negative control was only buffer. The inhibition effect 
of the fraction on PLA2 activity was determined through 
co-incubation for 30 min at 37°C of the enzyme and fraction 
at w/w ratios 1:1, 1:2, 1:5 and 1:10, just before assaying the 
residual PLA2 activity. After the incubation period, the sample 
was added to the assay and the reaction was monitored at 425 
nm for 40 min (at 10 min intervals) at 37°C. The quantity of 
chromophore released (4-nitro-3-hydroxy benzoic acid) was 
proportional to the enzymatic activity and the initial velocity 
(Vo) was calculated considering the absorbance measured 
in 20 min. 
Inhibition of cytotoxicity induced by PLA2
Inhibition experiments of the cytotoxic activity of PLA2 and 
PLA2 homologue by the fraction were performed on murine 
skeletal muscle C2C12 myoblasts or myotubes (ATCC CRL-
1772), as reported in the literature (Lomonte et al., 1999). 
Forty micrograms of each toxin were used in the assay. 
Inhibition experiments on B. atrox myotoxin I (Lys49) were 
performed on myoblasts, while inhibition assays on Cdcum6 
(Asp49) were carried out on myotubes. The type of cells was 
chosen due to the higher susceptibility of these cells to the 
action of the toxins (Núñez et al., 2004; Pereañez et al., 2009). 
Different w/w ratios (toxin: fraction, 1:2, 1:5 and 1:10) in 150 
μl of assay medium (Dulbecco’s Modified Eagle’s Medium 
supplemented with 1% fetal calf serum), were incubated at 
37°C for 30 min, and added to 96-well plates. After 3 h at 
37°C, a supernatant aliquot was collected for determination 
of lactic dehydrogenase activity (LDH; EC 1.1.1.27) released 
from damaged cells, using a kinetic assay (Wiener LDH-P UV). 
Controls of 0 to 100% toxicity consisted of assay medium and 
toxins, respectively. 
Inhibition of myotoxic activity
Inhibition of myotoxic activity in preincubation assays
Myotoxic of the PLA2 activity was determining estimated by 
the plasma levels of creatine kinase (CK; EC2.7.3.2) in groups 
of three mice (18-20 g body weight), after an intramuscular 
injection (in the gastrocnemius) of 20 μg of B. atrox myotoxin I 
(Lys49) or 3 μg of Cdcum6 (Asp49), either alone, or preincubated 
with the fraction at 1:1, 1:2, 1:5 and 1:10 w/w (toxin : fraction) 
ratios for 30 min at 37°C (Pereañez et al., 2009). Control groups 
received an identical injection (100 μl) of PBS, pH 7.2, alone, or 
fraction alone. After 3 h, blood samples were collected from 
the tail into heparinized capillary tubes, and the plasma CK 
activity of plasma was determined by a kinetic assay (Weiner 
Lab, CK-NAC UV-AA). Controls of 0 to 100% toxicity consisted 
of PBS and toxins, respectively. Experiments were carried out 
in duplicate.
Inhibition of myotoxic activity by independent in situ 
administration of fraction
The ability of fraction to inhibit myotoxicity by independent 
In situ administration was evaluated. Mice received an i.m. 
myotoxin injection (20 μg Myotoxin I or 3 μg of Cdcum6). 
Thirty seconds later several amounts of the fraction (in order 
to obtain 1:10, 1:5 and 1:2 w/w toxin: fraction ratios) were 
injected at the same site. Control animals received DMSO 
3% in PBS, or fraction alone (Pereañez et al., 2009). After 3 h, 
plasma creatine kinase activity was determined as described 
above. Results are shown in percentage of inhibition, taking 
the toxin and PBS injections 100% and 0% of activity, 
respectively. 
Inhibition of edema-inducing activity
Groups of three mice (18-20 g) received a subcutaneous 
injection of 50 μl of PLA2 (10 μg of Cdcum6 and 32 μg of B. atrox 
myotoxin I, equivalents to two minimum edematogenic doses) 
on the right footpad. The left footpad received 50 μl of DMSO 
3% in PBS as control. Inhibition studies were performed by 
pre-incubating fraction with PLA2 (in order to obtain 1:10 w/w 
ratios) for 30 min at 37°C. After injection, the progression of 
edema was evaluated with a caliper at intervals of 1, 2, 3, 6, 24 
h and expressed in millimeters (Pereañez et al., 2009). Control 
animals received fraction alone. 
Inhibition of anticoagulant activity
Ten micrograms of Cdcum6, in 10 μl PBS, were mixed with 90 
μl of different fraction of amounts of fraction (in order to obtain 
1:10, 1:5 and 1:2 w/w ratios) and pre-incubated for 30 min at 
37°C. Afterwards, 100 μl of mixtures were added to 0.3 ml of 
plasma, and incubated for 10 min at 37°C. Plasma aliquots 
incubated with PBS (fraction) or toxin used was the negative 
and positive controls, respectively. Then, coagulation times 
were recorded after adding 0.1 ml of 0.25 M CaCl2 (Gutiérrez 
et al., 1986).
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Inhibition of proteolytic activity
In order to determine the specific inhibition of the fraction on 
PLA2 induced activities, the capacity of the compounds to inhibit 
the proteolytic activity induced by Batx-I, (a metalloproteinase 
isolated from Bothrops atrox venom) (Patiño et al., 2010) and 
trypsin, was tested. Proteolytic activity was measured on 
azocasein (Sigma-Aldrich, St. Louis, MO) according to Wang et 
al. (2004), with some modifications. Briefly, 20 μg of proteases 
dissolved in 5 μl of 25 mM Tris (0.15 M NaCl, 5 mM CaCl2), pH 
7.4, were mixed with 200 μg and 100 μg of fraction (in order to 
obtain 1:10 and 1:5 w/w ratios, respectively) and pre-incubated 
for 30 min at 37°C. Afterwards, these solutions were incubated 
for 90 min at 37°C with 10 mg/ml of azocasein diluted in the 
same buffer. The reaction was stopped by the addition of 200 μl 
of trichloroacetic acid. Samples were then centrifuged at 360 g 
for 5 min. Supernatant (100 μl) was mixed with the equal volume 
of 0.5 M NaOH, and the absorbances were measured at 450 nm. 
Results are shown in percentage of activity (absorbance at 450 
nm). The assay was carried out in duplicate. 
Polyacrylamide gel electrophoresis (SDSPAGE)
SDS-PAGE was performed on 15% polyacrylamide gels (Laemmli, 
1970). The mixture of each toxin and several w/w ratios of toxin 
and the fraction (1:10, 1:5 and 1:1) was preincubated at 37°C for 
30 min. Then, 20 μl of each mixture was run at 120 V for 1 h. The 
proteins were stained with Coomassie blue.
Statistical analysis
In order to obtain significant differences between inhibitory effects 
of fraction each fraction on toxin, two-way ANOVA followed by 
Bonferroni´s test was applied. In anticoagulation activity, the one-
way ANOVA followed by Dunnet´s test was carried out. In all the 
cases p < 0.05 was considered significant, and the results shown 
are the mean ± SE of n indicated in each case.
Results
Bioassay-guided fractionation of Swietenia macrophylla
Altogether, 22 fractions were obtained after the initial 
fractionation, labeled as Sm 1 to 22. According to their 
similar thin layer chromatography profile, and having an 
inhibition of 48-60% of the enzymatic activity induced by 
B. asper whole venom (1:10 w/w ratio in egg yolk assay), 
fractions Sm 13 to 16 were combined as Sm13-16 and further 
fractionated into thirty fractions. The inhibitory ability on 
the PLA2 enzymatic activity induced by B. asper whole venom 
(1:10 w/w ratio in egg yolk assay) was performed on the 
thirty fractions, and promising results were observed with 
four of them (Table 1). Further inhibition assays of Cdcum6 
(Asp49, enzymatic activity) and B. atrox myotoxin I (Lys49, 
cytotoxic activity) were performed with these four fractions. 
Significant inhibitory activity on both myotoxins tested, was 
only obtained by Sm13-16, 23 (Table 1), thus this fraction was 
chosen for further inhibition experiments. 
Characterization of Sm13-16, 23
The spectral date obtained for Sm13-16, 23 were: UV Omax 
(nm) (MeOH): 655, 266 and 219. IR OmaxKBr (cm): Broad 
and intense peak between ~ 3600-3000 (OH), 2923.07 and 
1438.90 (C-H), 1656.69 (C = O), 1618.63 and 1607.67 (C-O), 
1285.47-772.60 (aromatic). Furthermore, in the colorimetric 
preliminary assays the presence of phenolic compounds such 
as flavonoids, leucoanthocyanidins and tannis were detected 
in Sm13-16, 23. 
Inhibition of PLA2 activity by Sm13-16, 23
In the bioassays using egg yolk and 4N3OBA as substrates, PLA2 
activity induced by Cdcum6 was inhibited in a dose dependent 
manner by Sm13-16, 23. However, the higher inhibitory activity 
was observed when aggregated substrate was used (egg yolk) 
(Table 2). In this assay, inhibition values between 73 to 95% 
were shown at 1:1, 1:2, 1:5 and 1:10 w/w ratios. Nevertheless, 
minor neutralization of PLA2 activity was observed when 
the monodisperse substrate (4N3OBA) was used, showing 
inhibition values between 0-21% when using the w/w ratios 
mentioned above. 
Inhibition of cytotoxic activity by Sm13-16, 23
The sample Sm13-16, 23 showed a dose dependent inhibition 
of the cytotoxic activity induced by Asp49 and Lys49 PLA2 
(Fig. 1). Significant difference between neutralization values 
obtained at 1:10 and 1:5 w/w ratios (toxin: sample) was 
observed inter and intra-toxin. However, the best inhibition 
percentages were always shown toward B. atrox myotoxin I. 
The fraction was not cytotoxic on C2C12 muscle cells (data 
not shown).






Sm13-16, 23 80.00 ± 5.77 93.87 ± 1.20 86.82 ± 4.93
Sm13-16, 24 66.67 ± 6.67
d 69.93 ± 4.22d 8.91 ± 2.88d 
Sm13-16, 27 50.00 ± 5.77 
d 54.51 ± 3.58d 23.89 ± 5.93d 
Sm13-16, 28 76.67 ± 8.82
d 72.99 ± 4.35d 25.25 ± 7.45d 
aInhibition of B. asper whole venom PLA2 induced activity using egg 
yolk as substrate and 10 μg venom. 1:10 w/w ratio was used. Results 
are shown as mean ± SE, n = 8. 
bInhibition of Cdcum6 (Asp49) PLA2 induced activity using egg yolk as 
substrate and 20 μg toxin. 1:10 w/w ratio was used. Results are shown 
as mean ± SE, n = 8. 
cInhibition of B. atrox myotoxin I (Lys49) cytotoxic induced activity 
on myoblasts using 20 μg toxin. 1:10 w/w ratio was used. Results are 
shown as mean ± SE, n = 6. 
dRepresent statistical differences regard to Sm13-16, 23.
Table 1
 Inhibition ability of the fractions obtained from Sm13-16.
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Inhibition of myotoxic activity by Sm13-16, 23
The inhibition of myotoxic activity induced by toxins was 
dose dependent (Fig. 2A and 2B). In both assays (preincubation 
and in situ administration) significant difference between 
neutralization values obtained at 1:10 and 1:5 w/w ratios (toxin: 
sample) was observed inter and intra-toxin. In contrast, only in 
preincubation assay significant difference at 1:2 and 1:1 ratios 
was observed (Fig. 2A). In both experiments, Cdcum6 was not 
inhibited by Sm13-16, 23 at a lowest ratios used (Fig. 2A and 
2B). 
PLA2 activity inhibition percentage (%)
Substrate
W/W ratioa
1:10 1:5 1:2 1:1 1:0.5 1:0.25
Egg yolkb 93.87 ± 1.20 87.38 ± 1.48 76.96 ± 1.37
d 75.78 ± 3.68d 30.66 ± 2.11d 5.76 ± 1.06d
4N3OBAc 21.51 ± 1.42 12.31 ± 1.72
e 2.59 ± 1.59e 0.0 ± 0.0e 0.0 ± 0.0e 0.0 ± 0.0e
aTwenty micrograms of Cdcum6 were used in all experiments. Different w/w ratios Cdcum6:fraction were assayed. Results are shown as 
mean ± SE as indicated in each case. 
bAssay with egg yolk as substrate, n = 8. 
cAssay with 4-nitro-3-octanoyloxy-benzoic acid (4N3OBA) as substrate, n = 12. 
dRepresents statistical differences regard to 1:10 w/w ratio when egg yolk was used as substrate. 
eRepresents statistical differences regard to 1:10 w/w ratio when 4N3OBA was used as substrate.
Table 2
Inhibition of PLA2 activity by Sm13-16, 23.
Figure 1 - Inhibition of cytotoxicity of PLA2s Sm13-16, 
23. Forty micrograms of each toxin and different w/w 
ratios were used, n = 6. Results are shown as mean ± SE. a 
Represents statistical differences regard to inhibition values 
1:10 w/w ratio on cytotoxic activity induced by myotoxin 
I of B. atrox. b Represents statistical differences regard to 
inhibition values 1:10 w/w ratio on cytotoxic activity induced 
by Cdcum6.
Figure 2. - Inhibition of PLA2-induced myotoxicity by Sm13-
16, 23. A, Inhibition of myotoxicity in preincubation assay; 
B, Inhibition of myotoxic activity by locally administered 
fraction. Twenty μg of B. atrox myotoxin I and 3 μg of 
Cdcum6 and different w/w ratios were used, n = 6. Results 
are shown as mean ± SE. a Represents statistical differences 
regard to inhibition values 1:10 w/w ratio on cytotoxic 
activity induced by myotoxin I of B. atrox. b Represents 
statistical differences regard to inhibition values 1:10 w/w 
ratio on cytotoxic activity induced by Cdcum6.
A
B
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Inhibition of anticoagulant activity by Sm13-16, 23
This sample exhibited a dose dependent inhibition on 
anticoagulant activity induced by Cdcum6 (Fig. 3). At all w/w 
ratios used, a significant inhibition was observed (p < 0.05). 
Sample Sm13-16, 23 did not display coagulant effect, showing 
comparable coagulation times with negative control.
Inhibition of edema-inducing activity by Sm13-16, 23
The highest edema-inducing activity of the two toxins was 
shown two hours after injection (Fig. 4). At this time, at 1:10 
Figure 3 - Inhibition of anticoagulant activity of aan Asp49 PLA2 by Sm13-16, 23. Ten micrograms of Cdcum6 and different w/w 
ratios were used, n = 6. a Represents statistical significant difference respect to toxin. Results are shown as mean ± SE.
Figure 4 - Inhibition of edema-inducing activity of PLA2 by Sm13-16, 23. Ten micrograms of Cdcum6 and 32 of B. atrox 
myotoxin I (equivalents to two minimum edematogenic doses) were used. 1/10 w/w ratio was tested, n = 6. a Represents 
statistical significant difference respect to each toxin at 2 h. Results are shown as mean ± SEM.
Figure 5 - Inhibition of proteolytic activity by Sm13-16, 23. Twenty micrograms of each protease were used. 1:10 and 1:5 w/w 
ratios was tested, n = 6. a Represents statistical significant difference respect to each protease. Results are shown as mean ± SE.
w/w ratio, edema caused by Cdcum6 was inhibited ~ 26% by 
Sm13-16, 23 (p < 0.001). Likewise, the edema induced by B. 
atrox myotoxin I was inhibited ~ 53% (p < 0.001). Significant 
edema-inducing activity was not shown by 332 micrograms 
of the fraction (the highest amount of fraction used in this 
assay). 
Inhibition of proteolytic activity by Sm13-16, 23
At all w/w ratios assayed, the proteolytic activity caused 
by Batx-I and Trypsin was not inhibited by Sm 13-16, 23 
(Fig. 5). 
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Polyacrylamide gel electrophoresis (SDSPAGE)
Sm13-16, 23 did not change the migration pattern of the toxins 
(Fig. 6A and 6B). In addition, the fraction apparently did not 
modify the molecular mass of the toxins, and was not stained 
with Coomassie Blue, evidencing the lack of proteins in this 
fraction (Fig. 6A and 6B). 
of venoms (Gutiérrez et al., 1998). Thus, there is a need to 
search for additional inhibitors and approaches that may be 
useful counterparts to conventional antivenom therapy. In 
this direction, the plant Swietenia macrophylla King, Meliaceae, 
was chosen from a pool of plants as a promising lead because 
of its neutralizing activity against Bothrops asper venom and 
a PLA2 isolated from it (Pereañez et al., 2010). After several 
bioassay-guided fractionation steps, the fraction Sm13-16, 23 
was obtained as the most active for its inhibitory ability of 
the myotoxic effect induced by PLA2s. In preincubation assays, 
the myotoxicity was successfully inhibited by 1:10 w/w ratios 
(~ 90%). However, when Sm13-16, 23 was injected immediately 
after poisoning, the myotoxicity was inhibited only to a minor 
extent. Nevertheless, the reduction in muscle damage is still 
significant since the major limitation for the development of 
any clinically effective inhibitor of myotoxins is the dramatic 
speed at which PLA2 affects skeletal muscle (Gutiérrez and 
Ownby, 2003). In addition, inhibition experiments using cell 
cultures, such as rodent lines of skeletal muscle myoblasts/
myotubes, appear to correlate with their in vivo myotoxicity 
(Lomonte et al., 1999). This relationship was used to confirm the 
results described above, since when PLA2 were pre-incubated 
with Sm13-16, 23 at different w/w ratios to the previous cell 
cytotoxic assay, the damage was significantly reduced. 
It is known that the action of Asp49 PLA2 over membrane 
phospholipids requires interfacial activation of the enzyme 
(Berg et al, 2001). Sm13-16, 23 inhibited PLA2 activity of Cdcum6 
on egg yolk (aggregated substrate). However, this activity was 
weakly neutralized when 4N3OBA (monodispersed substrate) 
was used. These results could be explained taking into account 
that in egg yolk assay, PLA2 performs interfacial activation and 
further phospholipid hydrolysis (Berg et al, 2001), whereas in 
4N3OBA assays only the hydrolytic activity of the enzyme 
is measured (in this assay PLA2 does not require interfacial 
activation to perform its activity). Therefore, these results 
indicate the possible interaction of Sm13-16, 23 compounds 
either on the interfacial binding surface (i-face) or the active 
site of the enzyme. The first interactions could also explain the 
inhibition of PLA2-induced anticoagulation. The mechanism 
of this type of enzymes is related to their capacity to interact 
by means of their “anticoagulation site” (residues 57-74) with 
factor X a during the coagulation cascade (Kini, 2005). However, 
it is known that some of these residues are implicated also in 
interfacial activation of the enzyme (Jain and Berg, 2006). In the 
same way, the inhibition of other activities induced by Lys49 
PLA2s, such as myotoxicity, could also be explained by a change 
in the overall charge of the interfacial binding surface of the 
PLA2 homologues. This was described by means of structural 
and in vivo studies for suramin. This compound caused 60% 
of the inhibition of myotoxicity induced by bothropstoxin I 
(Lys49 PLA2) (Murakami et al., 2007). On the other hand, edema 
caused by Asp49 and Lys49 PLA2 may be due to their combined 
effect to hydrolyze phospholipid membrane - resulting in the 
loss of membrane integrity - as well as their metabolic activity 
generating pro-inflammatory products such as eicosanoids, 
whose function is to amplify the inflammatory event (Teixeira 
et al., 2003). In addition, Lys49 PLA2-induced edema is related to 
their ability to interact, and destabilize biological membranes 
(Lomonte et al., 2003). Thus, the inhibitory effect showed by 
Figure 6 - SDS-PAGE of the Sm13-16, 23 preincubated with 
myotoxic PLA2. Twenty micrograms of each toxin were 
preincubated (30 min at 37°C) with several amounts of 
Sm13-16, 23, in order to obtain 1:10, 1:5 and 1:1 w/w ratios. A, 
Sm13-16, 23 mixed with Cdcum6, a. Molecular mass markers 
(200, 116.2, 97.4, 66.2, 45, 31, 21.5, 14.4, 6.5), b. 20 μg Cdcum6; 
c.1:10 w/w ratio cdcum6: Sm13-16, 23; d. 1:5 w/w ratio 
cdcum6: Sm13-16, 23; e.1:1 w/w ratio cdcum6: Sm13-16, 23; f. 
200 μg Sm13-16, 23, the highest quantity used in this assay. 
B, Sm13-16, 23 mixed with B. atrox Myotoxin I, a. Molecular 
mass markers (200, 116.2, 97.4, 66.2, 45, 31, 21.5, 14.4, 6.5), b. 
20 μg B. atrox Myotoxin I; c.1:10 w/w ratio B. atrox Myotoxin 
I: Sm13-16, 23; d. 1:5 w/w ratio B. atrox Myotoxin I: Sm13-16, 
23; e.1:1 w/w ratio B. atrox Myotoxin I: Sm13-16, 23; f. 200 μg 
Sm13-16, 23, the highest quantity used in this assay.
Discussion
PLA2-induced myotoxicity occurs in two clinical patterns: 
local and systemic (Warrell, 1996). The action of these 
enzymes may result in irreversible lesions which might 
lead to dysfunction and even amputation of the affected 
limb (Otero et al., 2002). Moreover, it has been demonstrated 
that antivenoms, the current therapy for snakebite, have a 
limited efficacy against the local tissue damaging activities 
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Sm13-16, 23 could be related to the inhibition of enzymatic 
activity and the change of the overall charge of the interfacial 
binding surface, as described above. 
In the effort to characterize Sm13-16, 23, the preliminary 
phytochemical qualitative analysis of Sm13-16, 23, was 
consistent with the detection of phenolic compounds. 
Additionally, the detection of the aromatic system by the UV 
and IR data, were comparable to those previously reported in 
the literature for phenolic compounds (Silverstein and Webster, 
1998). Therefore, the signals for the hydroxyl groups and the 
aromatic rings observed in IR spectrum support the detection 
of phenolic compounds in sample Sm13-16, 23. This is relevant, 
since these molecules can interact with the enzymes in several 
ways. This has been concluded, in several studies, in which 
the mode of interaction of polyphenolic compounds on PLA2 is 
due to the interactions between the enzyme and the hydroxyl 
groups present in this type of metabolites, through hydrogen 
bonds, that result in the formation of a stable complex 
(Chandra et al., 2002; Da Silva et al., 2009; Lindahl et al., 
1997). However, the activity of polyphenolic compounds may 
involve varying degrees of interactions such as hydrophobic 
connections mediated by aromatic rings, which should also 
be considered. 
In the specific case of polyphenols such as tannins, the 
inhibition on PLA2 could be due to unspecific binding and 
further precipitation of proteins (Haslam, 1996; Wall et al., 
1996). However, this is not likely to be the case in this study, 
because Sm13-16, 23 did not inhibit the enzymatic activity of 
other enzymes (snake venom metalloproteinase and trypsin). 
Therefore, these results indicated some specificity of this type 
of tannins toward PLA2s. Nevertheless, the presence of smaller 
molecules derived from gallotannins, such as ellagic acid and 
its O-methyl derivatives could be considered, since it has been 
reported to high inhibition ability of these molecules on snake 
venom PLA2 (da Silva et al., 2008). In the same way, results 
of SDS-PAGE suggests that Sm13-16, 23 does not form large 
complexes with the toxins, which also indicates that tannins 
of Sm13-16, 23 not unspecifically bind and precipitate proteins.
Considering the presence of other type of polyphenols 
in Sm13-16, 23, such as flavonoids, it these metabolites 
have been shown to exert inhibition of enzymatic and toxic 
effects of PLA2s (Iglesias et al, 2005; Lindahl et al., 1997). The 
inactivation of the enzyme by competitive inhibition has 
been proposed for these compounds (Lättig et al., 2007). 
Hence, this is in accordance with one of the possible mode 
of action for Sm13-16, 23 described above (interaction of 
Sm13-16, 23 compounds with active site of the enzyme). 
Other phenols like leucoanthocyanidins with a very similar 
structure as flavonoids, known systematically as flavan-3, 
4-diols, could have a similar mode of action as well. Moreover, 
these molecules are structurally and biosynthetically related 
to anthocyanidins (Springob et al., 2003), which have a 
considerable inhibitory activity over secreted PLA2s (Dreiseitel 
et al., 2009). 
In conclusion, we obtained a fraction from S. macrophylla 
leaves extract with promising inhibitory ability on myotoxic 
PLA2. This fraction, named as Sm13-16, 23, with a high content 
of phenolic compounds, inhibited enzymatic and anticoagulant 
activities of Asp49 PLA2 and also inhibited myotoxic and 
edema-forming activities of Asp49 and Lys49 PLA2s. However, 
Sm13-16, 23 was much more efficient to inhibit the toxic 
activities induced by the Lys49 PLA2 than the Asp49 PLA2. 
Our next goal is the isolation and elucidation of the chemical 
structure of compounds that occur in Sm13-16, 23 in order to 
contribute to the development of a novel product that could 
reduce the local effects in the snakebites, such as myotoxicity 
and edema.
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